Dr. Mark Kirchhof

Dermatologist, Ottawa, ON

Dr. Mark Kirchhof is the Division Head of Dermatology in the Faculty of Medicine at the University of Ottawa and The Ottawa Hospital. After receiving his Bachelor of Science in molecular biology from McMaster University, Dr. Kirchhof completed his medical degree and PhD at Western University in London, Ontario. His PhD research involved studies of the signalling pathways important to immune system regulation. He then went on to complete his dermatology residency at the University of British Columbia in Vancouver, British Columbia.
Until August 2017, Dr. Kirchhof was the Education Director at Queen’s University in Kingston, Ontario, where he coordinated and led undergraduate, post-graduate and continuing medical education activities. He has published over 80 peer-reviewed papers and maintains a keen interest in clinical and bench-to-bedside research. He has been invited to speak at local, national and international meetings. His clinical interests are varied and he sees both pediatric and adult patients.

1:05 PM - 1:55 PM

NOV 2 (Thu)

The Reason is Clear: Elevating Standards of Care in Psoriasis and Atopic Dermatitis

Given the evolution from traditional systemic therapies to advanced treatment options in both psoriasis and atopic dermatitis, physicians can aspire to gain control on the disease and optimize patient outcomes. This session will highlight the importance of advanced therapies in treating to higher standards of care and the significant impact it can have on patients’ quality of life.

In collaboration with:

3:00 PM - 3:50 PM

NOV 3 (Fri)

Unmet Needs in Atopic Dermatitis: Towards a Mechanistic Understanding


  1. Describe the burden of uncontrolled atopic dermatitis in different patient populations
  2. Summarise recent translational discovery underlying itch, and the pathophysiology and phenotypes of AD

There are unmet needs in the management of atopic dermatitis (AD), especially in underserved areas. Itch is the most universal symptom in patients with AD and is typically the most burdensome symptom. When asked about the frequency of itch in 110 patients with AD in Canada surveyed by CSPA and Eczema Quebec, over 70% mentioned that they experienced itch everyday in the past week. With recent translational discoveries, there have been substantial advances in the understanding of the phenotypes of AD, the sensation of itch and its molecular pathways from skin to brain. This Open Session will review the burden of uncontrolled AD in different patient populations, the molecular mechanisms underlying the pathophysiology of AD and the sensation of itch.